Objective: e objective of the study was to investigate whether hepatocellular carcinoma (HCC) histology is associated with clinical and computed tomographic/magnetic resonance imaging features and locoregional therapy (LRT) outcomes.
INTRODUCTION
Histological grades and cytological subtypes of hepatocellular carcinoma (HCC) have been established. [1] Previous studies suggest that high tumor grade is associated with tumor recurrence and decreased survival after orthotopic liver transplantation (OLT) among patients within Milan criteria and higher local tumor progression rates after radiofrequency ablation (RFA) among Barcelona clinic liver cancer (BCLC) Stage A patients. [2] [3] [4] High tumor grade on explant is also associated with lack of odds ratio (OR) to transcatheter arterial chemoembolization (TACE). [5] In regard to cytological subtype, the clear-cell variant has been associated with improved survival after surgical resection [6] [7] [8] though data conflicts. [9, 10] However, aforementioned studies predominantly include patients with early-stage disease and are not fully reflective of HCC populations treated with locoregional therapy (LRT). Further, tumor grade on explant after LRT may differ from before therapy. ere is also a paucity of literature on the prognostic value of cytological subtype in patients treated with LRT. is study was undertaken to assess the relationship between baseline histological features of HCC and clinical stage, computed tomographic (CT) and magnetic resonance imaging (MRI) features, and outcomes in patients treated with LRT.
SUBJECTS AND METHODS

Study cohort
is single-center retrospective cohort study was approved by our Institutional Review Board and in compliance with the Health Insurance Portability and Accountability Act, with a waiver of informed consent for retrospective review of medical records. Consecutive patients (n = 124, mean age 61 years; age range 30-85 years) at the University of Illinois Hospital with 132 percutaneous biopsy-proven HCC who subsequently underwent LRT were identified through retrospective chart review from 2008 to 2017. e cohort included 92 men with mean age of 59 years (range 30-85 years) and 32 women with mean age of 65 years (range 47-83 years). LRT modalities were transarterial chemoembolization (TACE, n = 51, 41%), percutaneous thermal ablation (n = 41, 33%), yttrium-90 (Y90) radioembolization (n = 17, 13%), and combination TACE/ablation (n = 15, 12%). Baseline BCLC stage was 0/A (n = 48, 38%), B (n = 33, 26%), C (n = 27, 22%), and D (n = 16, 13%). Mean tumor diameter was 4.8 cm ± 4.1 cm. e most common etiology of HCC was hepatitis C virus (38.7%). Ethnicity, gender, age, baseline laboratory values, Child-Pugh (CP) class, cirrhosis etiology, and type of LRT were tabulated [ Table 1 ]. e mean time from biopsy to LRT was 34 days (standard deviation, 60 days).
Locoregional therapies
LRT was performed by board-certified interventional radiologists with 2-20 years attending experience. Treatment modality was determined based on the BCLC staging algorithm and discussion in multidisciplinary tumor board. Y90 radioembolization was reserved for patients with multifocal and/or infiltrative disease, macrovascular invasion, and total bilirubin of <2.0 mg/dL. RFA under n (%) ultrasound (US) and CT guidance was performed using 14-gauge multi-tined electrodes (Starburst®, Angiodynamics, Inc. Latham, NY) per manufacturer protocol. Conventional TACE was performed as previously described. [11] ree thermal ablations were performed with microwave antennas (PR 15, NeuWave Medical, Madison, WI) per manufacturer protocol. For Y90 radioembolization, all patients underwent planning mesenteric angiography with Tc-99 macroaggregated albumin administration and predetermined dose of Y90 was administered at lobar (n = 16) or segmental level (n = 1) using SIR-Spheres® (n = 13) (SIRTex, Sydney, NSW) or eraspheres® (BTG, London, England) (n = 4). For patients treated with TACE/ablation, ablation was performed within 24 h of TACE.
Radiological assessment
Baseline contrast-enhanced multiphase CT (n = 74) or MR (n = 38) obtained within 1 month before LRT was assessed for arterial-phase hyperenhancement, venous or delayed phase washout, delayed capsular enhancement, macrovascular invasion, and tumor diameter as per Liver Imaging Reporting and Data System definitions. [12] Followup CT or MR images were prescribed 1 month after LRT and every 3 months thereafter to assess for residual tumor or recurrence. Tumor response and progression were determined according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) by board-certified radiologists with 4-9 years attending experience who were blinded to histological data. [13] Complete response (CR) and partial response (PR) were considered an objective response. For patients with more than one CT or MRI before LRT (n = 50), tumor volume doubling time was determined based on the Schwartz equation
where, T is the interval in days between two MR or CT studies, M0 is the 1 st time maximum diameter, M1 is the 2 nd time maximum diameter). [14] Median value of tumor volume doubling time was utilized to dichotomize the variable. [15] 
Histological analysis
Percutaneous biopsy specimens were obtained under US guidance with an 18-gauge core needle (BioPince™, Argon Medical Devices, Frisco, TX) and immediately fixed in formalin. Histological analysis was performed by a boardcertified pathologist (G.G). Eight patients (6%) had two biopsied HCC; one tumor was randomly selected per patient for inclusion in statistical analysis to maintain the independence of analyzed observations. Histological grade was classified by the Edmondson-Steiner (ES) system: [1] Grade 1 (well differentiated), Grade 2 (moderately differentiated), Grade 3 (poorly differentiated), and Grade 4 (pleomorphism). ES grade of 3 or 4 was defined as high grade. Cytology was classified as usual, clear, sclerosing, sarcomatoid, pleomorphic, fibrolamellar, steatohepatitis, or inflammatory type; specimens containing two or more subtypes were classified as mixed type. [1] Cytology was further categorized into three groups: 100% clear cell, focal clear cell (combination of clear cell and other variants), and absence of clear-cell components. [8] Architectural subtypes were classified as trabecular, pseudoglandular, and solid and specimens containing two or more subtypes were classified as mixed. [1] 
Clinical outcomes
Primary outcome measures were time to progression (TTP) after LRT and transplant-free survival (TFS). TTP was defined as the time from LRT to the detection of progression on imaging by mRECIST. TFS was defined as time from LRT to death or last clinical encounter; patients were censored at time of OLT.
Statistical analysis
Statistical analysis was performed using Statistical Analysis System (SAS) (2013, version 9.4; SAS Institute, Cary, NC). e association between two measurements was assessed on univariate analysis and by binary or multinomial logistic regressions when one of the measures was dichotomized or separated into >2 categories, respectively. To examine the impact of measurements on TTP and TFS, both univariate and stratified Cox proportional hazard models were fitted accordingly and Kaplan-Meier curves were created. Twosided P < 0.05 was considered statistically significant. A twosided P = 0.05-0.10 was considered a statistical trend.
RESULTS
Baseline biopsy and imaging characteristics
Tumors were ES Grade 1 (n = 13, 10.6%), 2 (n = 94, 76.4%), or 3 (n = 16, 13%) [ 
Baseline features associated with high ES grade and clearcell cytology by univariate analysis
High ES grade was associated with baseline α-fetoprotein (AFP) level >50 ng/ml (OR 4.6, 95% confidence interval [CI] 1.5-13.9; P = 0.007), BCLC Stage C (OR 4.5, 95% CI 1.3-16.4; P = 0.02), tumor diameter >5 cm (OR 3.1, 95% CI 1.1-9.0; P = 0.035), and infiltrative appearance (OR 5.0, 95% CI 1.5-16.2; P = 0.0007) [ Table 3 ]. ere was a trend toward shorter tumor volume doubling time (<155 days) with high ES grade (P = 0.09). About 100% clear-cell cytological variant was associated with non-viral cirrhosis (OR 5.3, 95% CI 1.6-17.2; P = 0.005) and both 100% clear cell and focal clear cell were associated solid architectural subtype (OR 6.3, 95% CI 1.8-21.9; P = 0.004 and OR 5.5, 95% CI 1.5-19.7; P = 0.009, respectively). Atypical contrast enhancement (lacking arterial-phase hyperenhancement or washout) was associated with 100% clear cell (OR 3.1, 95% CI 1.0-9.3; P = 0.046) but not with focal clear cell (OR 1.6, 95% CI 0.5-5.0; P = 0.44) in comparison to complete absence of clear cells. A trend was observed of clear-cell HCC being associated with lack of arterial-phase hyperenhancement (OR 3.2, 95% CI 0.9-11.1; P = 0.07) and comorbid diabetes mellitus (OR 2.6, 95% CI 1.0-6.7, P = 0.05). Clear-cell HCC was not associated with high tumor volume doubling time (OR 0.5, 95% CI 0.1-2.5, P = 0.39). Decreased TFS was observed with baseline tumor diameter >5 cm (HR 2.0, 95% CI 1.0-3.8; P = 0.05), tumor burden exceeding Milan criteria (HR 3.1, 95% CI 1.6-6.0; P = 0.001), CP Class C (HR 2.9, 95% CI 1.1-7.6; P = 0.03), BCLC Stage B (HR 3.9, 95% CI 1.7-9.0; P = 0.002), Stage C (HR 2.9, 95% CI 1.2-6.9; P = 0.02), Stage D (HR 5.2, 95% CI 1.8-15.0; P = 0.002), and macrovascular invasion (HR 3.0, 95% CI 1.2-7.9; P = 0.02) [ Table 4 ]. In addition, stable or progressive disease after LRT was associated with lower TFS (HR 2.4, 95% CI 1.2-4.9; P = 0.02).
High ES grade (HR 1.0, 95% CI 0. 
DISCUSSION
e baseline histological features of HCC underlying clinical presentation, radiologic features, and clinical outcomes following LRT are not fully understood. Prior studies that have demonstrated an association between histological subtype of HCC on recurrence and survival after resection, RFA, and transplant predominantly represent early-stage disease and histological assessment on surgical resection specimens or explant. [2] [3] [4] [5] In this study, histological information was assessed on percutaneous biopsy before LRT, and most patients (61%) were BCLC Stage B or greater. High tumor grade was significantly associated with aggressive tumor features such as large tumor diameter, elevated baseline serum AFP, and infiltrative appearance. In addition, the clear-cell variant was significantly associated with non-viral etiologies of cirrhosis and atypical contrast enhancement patterns on CT or MR images. While these findings suggest that tumor grade and cytological subtype in part underlie differences in baseline clinical and imaging features, such conventional histological information on percutaneous biopsy did not impart additional prognostic information from tumor stage and high-risk imaging features. [16] High ES has been associated with lack of objective response after drug-eluting embolic TACE in a retrospective cohort study of 93 patients who subsequently underwent OLT; however, the majority of patients were early stage, and histological differentiation was determined after TACE on explant. [5] In this study, no association was observed between high ES grade on percutaneous biopsy before LRT and objective response (OR 2.3, 95% CI 0.7-7.4; P = 0.15), suggesting that the predictive value of ES grade on posttherapy explant cannot be extrapolated to percutaneous biopsy specimens before LRT or patient populations with intermediate-or advanced-stage disease.
Poor histologic differentiation was associated with tumor diameter >5 cm, infiltrative appearance, and elevated serum AFP, supportive of prior studies. AFP is considered to be secreted by dedifferentiated HCC, [17] and infiltrative appearance on imaging is known to be associated with higher AFP levels and worse survival after intra-arterial therapy. [18] While tumor size, infiltrative appearance, and elevated AFP were associated with reduced TTP and TFS in this cohort, no such association was observed with histological features on univariate or stratified analysis. e predictive value of histologic differentiation on prognosis was limited by the fact that 70% of tumors with elevated AFP (>50 ng/ml), 75% of infiltrative HCC tumors, and 76% of tumors >5 cm were histologically low grade on percutaneous biopsy in this study. is is consistent with a retrospective study of 63 patients showing that tumor grade and microvascular invasion did not predict clinical response or overall survival after transarterial embolization or TACE in 50 patients with prior percutaneous core biopsy. [19] While poor tumor differentiation has been associated with local tumor progression in a study of 95 BCLC Stage 0/A patients treated with RFA, these findings are confounded by high-grade tumors being larger than low-grade tumors in the cohort and more frequent use of internally cooled electrodes with a higherpowered generator in the low-grade group. [4] Clear-cell HCC is distinguished from other variants by clear cytoplasm attributed to increased glycogen or lipid contents secondary to metabolic changes. [9] Such morphologic and metabolic changes may result from differential oncogenic process between chronic viral hepatitis and non-viral etiologies of cirrhosis such as alcohol and metabolic syndrome. [20] Furthermore, clear-cell variant of HCC is known to have decreased number of intratumoral arteries in association with fatty changes; this is supportive of its association with atypical enhancement on CT or MRI in this study. [21] A significant association was observed between clear-cell variants and the solid architectural subtype, but its biological and clinical significance remains to be determined in future study.
While poor tumor differentiation is associated with recurrence and poor survival after OLT or surgical resection, [2, 3] the impact of clear-cell HCC on prognosis is controversial: Some studies suggest that clear-cell variant is associated with longer overall survival, [6] [7] [8] while other studies found similar survival between clear and non-clear-cell variant tumors after surgical resection. [9, 10] It is postulated that longer survival in clear-cell variant is associated with relatively low histological grade and capsule formation that are favorable for surgery. [7] However, neither tumor grade nor clear-cell variant of HCC was associated with disease progression or TFS in our cohort after LRT.
Microvascular invasion on explant is strongly correlated with recurrence after OLT or surgical resection. [22, 23] In this study, a trend was observed toward a higher hazard of progression in tumors with microvascular invasion but not TFS. e lack of observed association in this study may be due to different methods to acquire HCC specimens: Percutaneous biopsy versus explant or surgical resection. In this cohort, only 13% of tumors were high ES grade and 9.1% demonstrated microvascular invasion on percutaneous core biopsy. In contrast, a study comprised 76% BCLC 0/A patients reported 53% were high ES grade and 51% had microvascular invasion on resection. [24] us, the lack of observed association between ES grade and microvascular invasion in the current study with treatment response, TTP, and TFS may Prior studies have demonstrated that percutaneous biopsy underestimates tumor grade and microvascular invasion compared to resection. [25] is study demonstrates that histological analysis of tumor grade can stratify HCC given its association with aggressive clinical and radiologic features. However, this study also supports the current practice of deferring conventional histological analysis before LRT in tumors diagnosed by imaging criteria [12] given the lack of independent prognostic information imparted by tumor grade and microvascular invasion on percutaneous biopsy. Although the prognostic value of conventional histological analysis before LRT may be limited, immunohistochemistry and genomic sequencing analysis of percutaneous biopsy specimens are under active investigation and percutaneous biopsy may yet prove critical to treatment allocation in the emerging era of precision medicine. Certain genetic mutations involved in Wnt/βcatenin and hypoxia stress response have been associated with objective response after transarterial embolization in primary and metastatic liver tumors. [26] Furthermore, high expression of programmed death ligand-1 on resected HCC specimens is associated with poor tumor differentiation, elevated AFP, microvascular invasion, [24] and poor diseasefree survival and overall survival. [27, 28] Our study bears several limitations. First, the retrospective single-institution design renders potential sampling bias in our cohort. Although the majority of tumors in this study demonstrated typical arterial-phase hyperenhancement and washout, a retrospective study of percutaneously biopsied HCC study will be inevitably enriched with HCC with non-diagnostic imaging features. Our cohort consisted of predominantly Caucasian and African-American patients with viral etiologies of HCC, and extrapolation of findings to other populations should be performed with caution. e relatively low number of patients with high ES grade (13%) in this cohort might have increased our susceptibility to a type II error. Similarly, while our study is unique in including BCLC B, C, and D patients, the variability in BCLC stage and LRT modality may have introduced confounding and reduced our ability to observe associations between histological features and outcomes. However, numerous tumor and clinical features, such as tumor size and BCLC stage, were significantly associated with TFS in this study; although a larger study may detect an association between histologic features on percutaneous biopsy on LRT outcomes, it is unlikely that histological features are superior prognostic indicators compared to macroscopic tumor features such as size and portal vein invasion, and clinical factors including BCLC stage. As discussed, studies utilizing percutaneous biopsy specimens are prone to histological misclassification bias due to non-representative tissue sampling of histologically heterogeneous tumors.
CONCLUSION
High histologic grade of HCC on percutaneous biopsy is associated with poor prognostic indicators such as larger tumors, infiltrative appearance, and advanced BCLC stage. e clear-cell variant of HCC was associated with non-viral cirrhosis, and the paucity of arteries in this subtype may underlie the atypical enhancement associated with these tumors. Percutaneous biopsy, therefore, may be used to diagnose HCC, but histological stratification did not provide independent prognostic information. e findings support deferral of percutaneous biopsy and histological assessment of HCC diagnosed by imaging criteria before LRT. 
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